2017 IAP Fall CME Meeting
Topics in Pathology
IU School of Medicine/IU Health
Fairbanks Hall
340 W 10th St
Indianapolis, Indiana 46202
Half-day- 3.0 hours CME*
(with opportunity for additional 1.0 credit from meeting collaborator--see below)
Light Breakfast and Lunch included
Presentations:
Mehdi Nassiri, MD (8:10-9:10)
Next generation sequencing for clinical decision-making, an evidence based approach
- Increase familiarity with the basis of evidence-based medicine
- Communicate the rationale behind different molecular assays and their necessity in different times
Robert Emerson, MD (9:10-10:10)
Common diagnostic dilemmas and a few pitfalls in gynecologic pathology
- Understand the difficult decision points and diagnostic dilemmas in endometrial pathology
- Recognize the common sources of diagnostic disagreement in uterine cervical pathology
- Discuss the common challenges in the complex area of ovarian neoplasia
Shaoxiong Chen, MD, PhD (10:30-11:30)
Immunostaining Markers in the Classification of Soft Tissue Tumors
- Correctly classify soft tissue tumors using immunostaining markers
- Be familiar with the sensitivity and specificity of immunostaining markers
- Describe four variants of rhabdomyosarcoma (RMS)
* CME Accreditation: The Indiana Association of Pathologists is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.
Collaborative Presentation:
A live activity offered for 1.0 CME AMA PRA Category 1TM credit-- Jointly provided by PCME and Rockpointe. This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Brandon T. Larsen, MD, PhD (12:00-1:00)
Senior Associate Consultant and Assistant Professor
Department of Laboratory Medicine and Pathology
Mayo Clinic Arizona
Scottsdale, AZ
Histopathological Patterns of Interstitial Lung Disease: A Multidisciplinary Approach to Distinguishing the Most Common Forms of Lung Fibrosis
1. Recognize the clinical features of ILD and differentiate histological patterns of lung fibrosis common in IPF, CTD-ILD, CHP, distinguishing IPF from other pulmonary conditions.
2. Recognize the importance and limitations of multidisciplinary discussion in the diagnosis of fibrotic interstitial lung diseases.